Future potential and status of selective sodium channel blockers for the treatment of pain

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 5, 2009, Pages 682-692

  Priest, Birgit T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Analgesic; Chronic pain; Drug discovery; Voltage gated sodium channel

Indexed keywords

A 803467; ANALGESIC AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; CO 102862; COCAINE; ESLICARBAZEPINE ACETATE; HARKOSERIDE; LAMOTRIGINE; LIDOCAINE; LIDOCAINE ETHOBROMIDE; MEXILETINE; OXCARBAZEPINE; RALFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; TECTIN; TETRODOTOXIN; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL; VX 409;

ASSAY; BINDING ASSAY; CELL MEMBRANE; CLINICAL TRIAL; DIABETIC NEUROPATHY; DRUG BLOOD LEVEL; DRUG STRUCTURE; ELECTROPHYSIOLOGY; HUMAN; NERVE CELL; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; POSTHERPETIC NEURALGIA; RECEPTOR BINDING; REVIEW; SODIUM CHANNELOPATHY; STRUCTURE ACTIVITY RELATION; TECHNOLOGY; TREATMENT FAILURE; TRIGEMINUS NEURALGIA;

ANALGESICS; ANIMALS; DRUG DESIGN; HUMANS; MEMBRANE POTENTIALS; MOLECULAR STRUCTURE; NERVE TISSUE PROTEINS; NEUROPEPTIDES; PAIN; SIGNAL TRANSDUCTION; SODIUM; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70149097762     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Cortright DN, Szallasi A; TRP channels and pain. Curr Pharm Des (2009) 15(15): 1736-1749.
2. Bayliss DA, Barrett PQ; Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact. Trends Pharmacol Sei (2008) 29(11):566-575.
3. 3. Linhart O, Obreja O, Kress M: The inflammatory mediators serotonin, prostaglandin E2 and bradykinin evoke calcium influx in rat sensory neurons. Neuroscience (2003 118(1: 69-74. (Pubitemid 36369531
4. + channels. Physiological Rev (1991) 71(4): 1047-1080.
5. Catterall WA: From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron (2000) 26(1): 13-25.
6. Isom LL: Sodium channel ß subunits: Anything but auxiliary. Neuroscientist (2001) 7(1); 42-54.
7. 7. Catterall WA, Goldin AL, Waxman SG: International Union of Pharmacology. XXXIX. Compendium of voltage-gated ion channels: Sodium channels. Pharmacol Rev (2003 55(4: 575-578. (Pubitemid 37500516
8. 8. Black JA, Dib-Hajj S, McNabola K, Jeste S, Rizzo MA, Kocsis JD, Waxman SG: Spinal sensory neurons express multiple sodium channel α-subunit mRNAs. Brain Res Mol Brain Res (1996)43(1-2):117-131. (Pubitemid 27042398)
9. 9. Kim CH, Oh Y, Chung JM, Chung K: The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. Brain Res Mol Brain Res (2001)95(1-2):153-161. (Pubitemid 33000374)
10. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L et al: An SCN9A channelopathy causes congenital inability to experience pain. Nature (2006) 444(7121):894-898.
11. v1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet (2007) 71(4);311-319.
12. 12. Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, Fan J, Bu D, Liu B, Fan Z, Wu G et al: Mutations in SCN9A, encoding a sodium channel a subunit, in patients with primary erythermalgia. J Med Genet (2004) 41(3); 171-174. (Pubitemid 38333793)
13. 13. Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Wang Y, Tyrrell L, Wang X, Yang Y, Waxman SG; Sporadic onset of erythermalgia: A gain-of-function mutation in Nav1.7. Ann Neurol (2006) 59(3):553-558. (Pubitemid 43358077)
14. 14. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, Rees M; SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron (2006) 52(5):767-774. (Pubitemid 44828442)
15. v1.7 (PNl) in acute and inflammatory pain. Proc Natl Acad Sci USA (2004) 101(34): 12706-12711.
16. Waxman SG, Kocsis JD, Black JA: Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol (1994) 72(1);466-470.
17. 17. Beckh S, Noda M, Lubbert H, Numa S; Differential regulation of three sodium channel messenger RNAs in the rat central nervous system during development. EMBO J (1989 8(12: 3611-3616. (Pubitemid 20016038
18. Dib-Hajj SD, Fjell J, Cummins TR, Zheng Z, Fried K, LaMotte R, Black JA, Waxman SG: Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain (1999) 83(3);591-600.
19. v1.3 null mutant mice. Mol Pain (2006) 2:33.
20. 20. Akopian AN, Sivilotti L, Wood JN; A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature (1996) 379(6562): 257-262. (Pubitemid 26025211)
21. 21. Sangameswaran L, Delgado SG, Fish LM, Koch BD, Jakeman LB, Stewart GR, Sze P, Hunter JC, Eglen RM, Herman RC: Structure and function of a novel voltage-gated, tetrodotoxin-resistant sodium channel specific to sensory neurons. J Biol Chem (1996) 271(11):5953-5956. (Pubitemid 26095390)
22. v1.8 (SNS/PN3): Expression and correlation with membrane properties in rat nociceptive primary afferent neurons. J Physiol (2003) 550 (Pt3):739-752.
23. 23. Porreca F, Lai J, Bian D, Wegert S, Ossipov MH, Eglen RM, Kassotakis L, Novakovic S, Rabert DK, Sangameswaran L, Hunter JC: A comparison of the potential role of the tetrodotoxininsensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci USA (1999) 96(14):7640-7644. (Pubitemid 29328333)
24. 24. Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC, Porreca F: Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, Nav1.8. Pain (2002) 95(1-2); 143-152. (Pubitemid 34076786)
25. Khasar SG, Gold MS, Levine JD: A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat. Neurosci Lett (1998) 256(1);17-20.
26. v1.8 (PN3/SNS) in a rat model of visceral pain. J Neurosci (2001) 21(21);8690-8696.
27. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, Smith A, Kerr BJ, McMahon SB, Boyce S, Hill R et al: The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci (1999) 2(6);541-548.
28. v1.8 in NGF-induced hyperalgesia, but not neuropathic pain. Neuroreport (2001) 12(14);3077-3080.
29. v1.8 (SNS/PN3)-null mice. J Neurosci (2002) 22(19):8352-8356.
30. v1.8. Mol Pain (2005) 1:24.
31. 31. Hillsley K, Lin JH, Stanisz A, Grundy D, Aerssens J, Peeters PJ, Moechars D, Coulie B, Stead RH; Dissecting the role of sodium currents in visceral sensory neurons in a model of chronic hyperexcitability using Nav1.8 and Nav1.9 null mice. J Physiol (2006) 576(Pt 1): 257-267. (Pubitemid 44426234)
32. v1.8 is essential for pain at low temperatures. Nature (2007) 447(7146):855-858.
33. + current in nociceptors. Proc Natl Acad Sci USA (1996) 93:1108-1112.
34. 2 modulates TTX-R I in rat colonic sensory neurons. J Neurophysiol (2002) 88(3): 1512-1522.
35. 35. Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG: NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc Natl Acad Sci USA (1998) 95(15);8963-8968. (Pubitemid 28350597)
36. v1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci USA (2005) 102(26): 9382-9387.
37. v1.9. J Physiol (2008) 586(4);1077-1087.
38. Cummins TR, Dib-Hajj SD, Black JA, Akopian AN, Wood JN, Waxman SG; A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J Neurosci (1999) 19(24):RC43.
39. v1.9, in mouse dorsal root ganglion neurons. Pflugers Arch (2004) 449(1); 76-87.
40. v1.9: A sodium channel with unique properties. Trends Neurosci (2002) 25(5):253-259.
41. v1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci (2006) 26(50);12852-12860.
42. + current in rat and mouse sensory neurones. J Physiol (2005) 567(Pt 3):851-867.
43. Persson AK, Gebauer M, Jordan S, Metz-Weidmann C, Schulte AM, Schneider HC, Ding-Pfennigdorff D, Thun J, Xu XJ, Wiesenfeld-Hallin Z, Darvasi A et al: Correlational analysis for identifying genes whose regulation contributes to chronic neuropathic pain. Mol Pain (2009) 5:7.
44. Cestèle S, Catterall WA: Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie (2000) 82(9-10):883-892.
45. Strichartz GR: The inhibition of sodium currents in myelinated nerve by quaternary derivatives of lidocaine. J Gen Physiol (1973) 62(1):37-57.
46. Courtney KR; Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther (1975) 195(2): 225-236.
47. 47. Scholz A: Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth (2002) 89(1):52-61. (Pubitemid 34778103)
48. 48. Schreibmayer W, Lester HA, Dascal N; Voltage clamping of Xenopus laevis oocytes utilizing agarose-cushion electrodes. Pflugers Arch (1994) 426(5);453-458. (Pubitemid 24088000)
49. Schroeder K, Neagle B, Trezise DJ, Worley J; IonWorks HT: A new high-throughput electrophysiology measurement platform. J Biomol Screen (2003) 8(1);50-64.
50. 50. Finkel A, Wittel A, Yang N, Handran S, Hughes J, Costantin J; Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J Biomol Screen (2006) 11(5):488-496. (Pubitemid 44223000)
51. Priest BT, Swensen AM, McManus OB: Automated electrophysiology in drug discovery. Curr Pharm Des (2007) 13(23):2325-2337.
52. Castle N, Printzenhoff D, Zellmer S, Antonio B, Wickenden A, Silvia C: Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. Comb Chem High Throughput Screen (2009) 12(1):107-122.
53. Papke RL, Smith-Maxwell C: High throughput electrophysiology with Xenopus oocytes. Comb Chem High Throughput Screen (2009) 12(1):38-50.
54. 3H]-lifarizine, a high affinity probe for inactivated sodium channels. Br J Pharmacol (1995) 115(6):1103-1109.
55. Catterall WA, Morrow CS, Daly JW, Brown GB: Binding of batrachotoxinin A 20-α-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem (1981) 256(17):8922-8927.
56. 56. Priest BT, Garcia ML, Middleton RE, Brochu RM, Clark S, Dai G, Dick IE, Felix JP, Liu CJ, Reiseter BS, Schmalhofer WA et al: A disubstituted succinamide is a potent sodium channel blocker with efficacy in a rat pain model. Biochemistry (2004) 43(30):9866-9876. (Pubitemid 38993836)
57. 57. Williams BS, Felix JP, Priest BT, Brochu RM, Dai K, Hoyt SB, London C, Tang YS, Duffy JL, Parsons WH, Kaczorowski GJ et al: Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry (2007) 46(50): 14693-14703. (Pubitemid 350276373)
58. v1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol (2008) 74(5): 1476-1484.
59. 59. Felix JP, Williams BS, Priest BT, Brochu RM, Dick IE, Warren VA, Yan L, Slaughter RS, Kaczorowski GJ, Smith MM, Garcia ML; Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. Assay Drug Dev Technol (2004) 2(3);260-268. (Pubitemid 39069632)
60. m dye: On-target and off-target effects of diverse pharmacological agents. J Biomol Screen (2006) 11(1):29-39.
61. Huang CJ, Harootunian A, Maher MP, Quan C, Raj CD, McCormack K, Numann R, Negulescu PA, Gonzalez JE: Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat Biotechnol (2006) 24(4):439-446.
62. Bugianesi RM, Augustine PR, Azer K, Dufresne C, Herrington J, Kath GS, McManus OB, Napolitano CS, Rush A, Sachs J, Simpson N et al: A cell-sparing electric field stimulation technique for high-throughput screening of voltage-gated ion channels. Assay Drug Dev Technol (2006) 4(1);21-35.
63. Binshtok AM, Bean BP, Woolf CJ; Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature (2007) 449(7162):607-610.
64. 64. Kalso E, Tramer MR, McQuay HJ, Moore RA: Systemic local-anaesthetic-type drugs in chronic pain: A systematic review. Eur J Pain (1998) 2(1):3-14. (Pubitemid 28248315)
65. Endo Pharmaceuticals reports first quarter 2009 financial results. Endo Pharmaceuticals Holdings lnc, Pennsylvania, PA, USA (2009). phx.corporate-ir. net/phoenix.zhtml?c=123046&p=irol-newsArticle&ID=1281818&highlight
66. Campbell FG, Graham JG, Zilkha KJ; Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry (1966) 29(3): 265-267.
67. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O: Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): Double blind crossover trial. Diabetologia (1969) 5(4):215-218.
68. Wilton TD; Tegretol in the treatment of diabetic neuropathy. S Afr Med J (1974) 48(20); 869-872.
69. 69. Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, Quessy S, Blum D, Grainger J, White J, Silver M: Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain (2006) 128(1-2): 169-179. (Pubitemid 46216610)
70. 70. Wallace MS, Rowbotham M, Bennett GJ, Jensen TS, Pladna R, Quessy S: A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. J Pain (2002) 3(3);227-233. (Pubitemid 34663612)
71. 71. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH; Algorithm for neuropathic pain treatment: An evidence based proposal. Pain (2005) 118(3):289-305. (Pubitemid 41752987)
72. + channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain (2003) 102(1-2):17-25.
73. Zuliani V, Patel MK, Fantini M, Rivara M: Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential. Curr Top Med Chem (2009) 9(4);396-415.
74. Matulenko MA, Scanio MJ, Kort ME: Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem (2009) 9(4): 362-376.
75. 75. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y; Oxcarbazepine in painful diabetic neuropathy: A randomized, placebo-controlled study. Eur J Pain (2005) 9(5): 543-554. (Pubitemid 41219786)
76. v1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA (2007) 104(20); 8520-8525.
77. v1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J Med Chem (2008) 51(3):407-416.
78. v1.7 blockers: Potential treatments for neuropathic pain. Bioorg Med Chem Lett (2007) 17(16):4630-4634.
79. Hoyt SB, London C, Ok H, Gonzalez E, Duffy JL, Abbadie C, Dean B, Felix JP, Garcia ML, Jochnowitz N, Karanam BV et al: Benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain. Bioorg Med Chem Lett (2007) 17(22): 6172-6177.
80. 80. London C, Hoyt SB, Parsons WH, Williams BS, Warren VA, Tschirret-Guth R, Smith MM, Priest BT, McGowan E, Martin WJ, Lyons KA et al: Imidazopyridines: A novel class of hNav1.7 channel blockers. Bioorg Med Chem Lett (2008) 18(5):1696-1701. (Pubitemid 351318238)
81. v1.6 voltage-dependent sodium channel. Am J Physiol Cell Physiol (2007) 293(2);C783-C789.
82. 82. Ok D, Li C, Abbadie C, Felix JP, Fisher MH, Garcia ML, Kaczorowski GJ, Lyons KA, Martin WJ, Priest BT, Smith MM et al: Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers. Bioorg Med Chem Lett (2006) 16(5);1358-1361. (Pubitemid 43143022)
83. 83. Shao PP, Ok D, Fisher MH, Garcia ML, Kaczorowski GJ, Li C, Lyons KA, Martin WJ, Meinke PT, Priest BT, Smith MM et al: Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain. Bioorg Med Chem Lett (2005) 15(7);1901-1907. (Pubitemid 40380756)
84. 84. Dimmock JR, Puthucode RN, Smith JM, Hetherington M, Quail JW, Pugazhenthi U, Lechler T, Stables JP; (Aryloxy)aryl semicarbazones and related compounds: A novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. J Med Chem (1996) 39(20); 3984-3997. (Pubitemid 26327435)
85. Ilyin VI, Hodges DD, Whittemore ER, Carter RB, Cai SX, Woodward RM; V102862 (CO 102862): A potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels. Br J Pharmacol (2005) 144(6):801-812.
86. Brochu RM, Dick IE, Tarpley JW, McGowan E, Gunner D, Herrington J, Shao PP, Ok D, Li C, Parsons WH, Stump GL et al: Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats. Mol Pharmacol (2005) 69(3):823-832.
87. PFIZER INC (Lane CAL, Maw GN, Rawson DJ, Thompson LR): Pyridine derivatives. WO-2006011050 (2006).
88. PORTELA & CA SA (Vieira Araújo Soares Da Silva PM): Use of 5H-dibenz[b,f]azepine-5-carboxamide derivatives in the treatment of neuropathic pain. WO-2007094694 (2007).
89. v1.7 sodium channel blockers. WO-2007109324 (2007).
90. ICAGEN INC (Beaudoin S, Johnson MS, Marron BE, Suto MJ): Sodium channel inhibitors. WO-2009012241 (2009).
91. ICAGEN INC (Fulp AB, Johnson MS, Markworth CJ, Marron BE, Seconi DC, West CW, Wang X, Zhou S); Sodium channel inhibitors. WO-2009012242 (2009).
92. MERCK & Co (Chakravarty PK, Fisher MH, Parsons WH, Liang J, Zhou B): Biaryl substituted 6-membered heterocycles as sodium channel blockers. US-20060293339 (2006).
93. MERCK & Co (Chakravarty PK, Fisher MH, Zuegner LL, Parsons WH, Palucki B, Zhou B, Park MK); Biaryl substituted triazoles as sodium channel blockers. US-20080171777 (2008).
94. GLAXO GROUP LTD (Johnson CN, MacPherson DT, Trani G); Pyridine derivatives as sodium channel blockers. WO-2008017691 (2008).
95. GLAXO GROUP LTD (Alvaro G, Bergauer M, Giovannini R, Profeta R); Prolinamide derivatives as sodium channel modulators. WO-2007042239 (2007).
96. VERTEX PHARMACEUTICALS INC (Martinborough E, Neubert T, Whitney T, Lehsten D, Hampton T, Zimmerman N, Termin AP); Ion channel modulators and methods of use. US-20080293737 (2008).
97. ASTRAZENECA AB (Besidski Y, Claesson A); Phenyl-1,2 3,4- tetrahydroisoquinolinone derivatives and their use in the treatment of a pain disorder. WO-2009005459 (2009).
98. v1.7 sodium channels for the treatment of pain disorders. WO-2009005460 (2009)
99. ASTRAZENECA AB (Besidski, Y, Claesson, A, Maksari I, Sandberg L): New compounds 955. WO-2009010784 (2009).
100. NEWRON PHARMACEUTICALS SPA (Thaler F, Napoletano M, Sabido-David C, Moriggi E, Caceia C, Faravelli L, Restivo A, Salvati P); 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators. WO-2007071311 (2007).